Most active Nasdaq-traded stocks
AP - 1 hr ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
GILD: 102.06 (-2.14), GERN: 2.76 (+0.45), ARCP: 8.73 (-0.08), MSFT: 49.58 (-0.03), AAPL: 114.18 (+1.36), CSCO: 26.32 (+0.64)
Final Glance: Biotechnology companies
AP - 1 hr ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Midday Glance: Biotechnology companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.43 (-12.55), VRTX: 111.34 (-1.38), GILD: 102.06 (-2.14), ALXN: 188.76 (-4.83), AMGN: 157.68 (-3.17), IBB: 288.17 (-5.72), REGN: 395.20 (-7.43), CELG: 104.05 (-3.38)
Early Glance: Biotechnology companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Gilead Sciences (GILD) Crosses Pivot Point Support at $102.79
Comtex SmarTrend(R) - Fri Nov 14, 8:57AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $104.92 and have already reached the first level of support at $102.79. Investors may be interested in a cross of the next downside pivot targets of $101.38 and $97.84.
GILD: 102.06 (-2.14)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), SNY: 46.68 (+0.15), REGN: 395.20 (-7.43)
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 102.06 (-2.14), IBIO: 1.05 (-0.03), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02), CELG: 104.05 (-3.38)
Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com
PR Newswire - Fri Nov 14, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: BlackBerry (NASDAQ:BBRY), Twitter (NYSE:TWTR), Alibaba (NYSE:BABA), Sirius XM (NASDAQ:SIRI), Gilead Sciences (NASDAQ:GILD), and JD.Com (NASDAQ:JD).
GILD: 102.06 (-2.14), BBRY: 11.20 (-0.86), JD: 27.01 (-0.31), TWTR: 41.85 (+1.81), SIRI: 3.53 (+0.02), BABA: 115.10 (+0.26)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.16 (-0.91), GILD: 102.06 (-2.14), MRK: 59.07 (-0.47), ABBV: 64.00 (+0.37)
If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST
GILD: 102.06 (-2.14), ABBV: 64.00 (+0.37)
Gilead prices debt offering
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:19AM CST
GILD: 102.06 (-2.14)
Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:44AM CST
Gilead Sciences which is in the Biotechnology space, saw EPS growth of nearly 11% last year, and is looking great for this year too.
GILD: 102.06 (-2.14)
Gilead prices USD4bn senior unsecured notes in three tranches
M2 - Thu Nov 13, 6:01AM CST
Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) said on Wednesday that it has priced its USD4bn senior unsecured notes in a public offering.
GILD: 102.06 (-2.14)
Gilead Prices $4 Billion of Senior Unsecured Notes
Business Wire - Wed Nov 12, 4:59PM CST
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion, in an underwritten, registered public offering, consisting of three tranches:
GILD: 102.06 (-2.14)